Discovery Laboratories, Inc. is a biotechnology company developing surfactant replacement therapies (SRT) to treat respiratory disorders and diseases. It novel technology (KL4 Surfactant Technology) produces a synthetic, peptide-containing surfactant (KL4 Surfactant) that is structurally similar to pulmonary surfactant, a substance produced naturally in the lung and essential for survival and normal respiratory function. In addition, its capillary aerosol generating technology (Capillary Aerosolization Technology) produces a dense aerosol with a defined particle size, to deliver its aerosolized KL4 Surfactant to the deep lung. The Company focuses on developing its products, Surfaxin, Surfaxin LS and Aerosurf, to address the most significant respiratory conditions affecting pediatric populations.